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Abstract
To compare overall number of downstream tests and total costs between negative exercise stress echocardiograms (ESE) or
cardiac computed tomography angiography scans (CCTA) in symptomatic Tricare beneficiaries suspected of having coronary
artery disease (CAD). This is a retrospective cohort study examining 651 propensity-matched patients who underwent ESE
or CCTA with normal results between 2008 and 2014 at the United States’ largest Department of Defense hospital. The total
number of additional downstream tests over the next five years was determined. The total costs associated with each arm,
inclusive of the initial test and all subsequent tests, were calculated using the 2018 Medicare Physician Fee Schedule. 18.5
percent of patients with a normal ESE result underwent some additional form of cardiac testing over the five years after initial
testing compared to 12.8 percent of patients with a normal CCTA. The absolute difference in total number of downstream
tests between both study groups was 5.7 percent (p = 0.03). When factoring the costs of the initial test as well as the downstream tests, the ESE group was associated with overall lower costs compared to the CCTA group, 351 United States Dollars
(USD) versus 496 USD (p < 0.0001). This study demonstrates that, when compared to CCTA, ESE is associated with a higher
total number of downstream tests, but overall lower total costs when chosen as initial testing strategy for suspected CAD.
Keywords Cardiac CT · Stress echocardiography · Downstream testing · Coronary artery disease

Introduction
Coronary artery disease (CAD) remains a leading cause of
death around the world. The clinician evaluating the patient
suspected of having symptoms attributable to stable obstructive CAD is confronted with the decision of choosing the
most appropriate test. Exercise stress echocardiography
(ESE) is a well-validated form of functional testing boasting a high sensitivity and specificity for the detection of
obstructive CAD with the notable benefits of widespread
availability and the absence of ionizing radiation exposure.
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Cardiac computed tomography angiography (CCTA) has
established itself as a commonly utilized noninvasive alternative to invasive coronary angiography for anatomic evaluation of coronary anatomy. Multiple randomized controlled
trials and subsequent meta-analyses have demonstrated that
CCTA can reliably exclude obstructive CAD with a very
high sensitivity and negative predictive value (NPV) [1–4].
Furthermore, two randomized controlled trials (RCTs), the
Prospective Multicenter Imaging Study for Evaluation of
Chest Pain (PROMISE) and Scottish Computed Tomography of the Heart (SCOT-HEART) trials, have confirmed
the utility of an anatomic approach to CAD detection when
compared to a functional stress-testing approach for outpatients with intermediate pre-test risk who present in the
outpatient setting with symptoms concerning for obstructive
CAD [5, 6]. However, few studies have directly compared
ESE directly with CCTA. Of relevance to our study design,
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Hadamitzky et al. have shown that the event-free five-year
survival is greater than 97% in patients without obstructive
disease on CCTA [7]. In light of this, some authors have
described a “warranty period” following a normal CCTA
[8]. Given that many clinicians may feel more comfortable
forgoing additional testing with normal CCTA results, our
study was designed to specifically examine the downstream
consequences of patients undergoing CCTA or ESE who
have an initial negative test result.

Methods
Study design
This is a retrospective study of symptomatic patients without
known CAD who underwent noninvasive testing for CAD
between the January 1, 2008 and June 31, 2014 at Brooke
Army Medical Center, the largest hospital in the Department
of Defense. The aim of the study was to compare the downstream consequences between those with a negative test
result when initial testing was ESE or CCTA. The patient
population includes active-duty personnel, their family
members, and retired military beneficiaries. The electronic
medical record was queried to identify individuals who
underwent cardiac stress testing during the study period. To
be included in the study, patients required symptoms potentially attributable to myocardial ischemia (see Table 1), had
to be between 45 and 70 years old at the time of initial testing, have a minimum presence of one cardiac risk factor
and have a normal initial test result. Indications for testing
were obtained by reviewing the patient’s electronic medical record. Normal CCTA was defined as Coronary Artery
Disease Reporting and Data System (CAD-RADS) 2 or
Table 1  Baseline characteristics
prior to propensity matching
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Male Sex, no. (%)
Age (years)
Mean ± SD
Range
Hypertension, no. (%)
Hyperlipidemia, no. (%)
Diabetes mellitus, no. (%)
Active smoker, no. (%)
CAD consortium score (%)
Indication, no. (%)
ATCP
Angina
Dyspnea
Palpitations
Syncope
Other

less. This equates to absence of any stenosis greater than
50%. Stress echocardiography was considered normal if the
patient reached target heart rate and normal augmentation
of ejection fraction and absence of any stress-induced wall
motion abnormality. Electrocardiographic changes, blood
pressure response, and other non-imaging portions of ESE
were not included in our study. Exclusion criteria included
low pretest cardiovascular risk defined as CAD Consortium
Score of less than 5%, and an abnormal or non-diagnostic
initial cardiac testing.
Measures were taken to protect the privacy of the subjects. Those who met the inclusion criteria were assigned
a unique study code which did not contain any personally
identifiable information. The subject identifiers required for
data collection were maintained separately from the study
database in a secure, password-protected location. Upon
completion of the study, the master file was deleted, rendering the data set de-identified.
Each subject’s gender, cardiac risk factors, study indication, study result, and downstream tests completed within
five years of the initial evaluation were documented and
analyzed. Downstream tests were defined specifically as
additional tests evaluating for myocardial ischemia. Costs
of downstream testing were determined using the Medicare
Physician Fee Schedule 2018 final rule.
Data analysis was performed using the Statistical Analysis System (SAS) software, including two-sided Chisquared testing of categorical variables, analysis of variance
(ANOVA) of continuous variables with normal distribution,
and Wilcoxon signed-rank test and the Kruskal–Wallis Test
for non-normally distributed continuous variables. Univariate and multivariate regression were completed to determine factors that might lead to increased testing. Propensity
CCTA (n = 1285)

Stress Echo (n = 327)

p-value

790 (61%)

180 (55%)

0.0347

52 ± 8.9
35–70
661 (51%)
606 (47%)
152 (12%)
150 (12%)
6.1 ± 8.1

53 ± 8.7
35–70
180 (55%)
151 (46%)
63 (19%)
32 (10%)
10.4 ± 11.1

0.783

989 (77%)
29 (2%)
45 (4%)
56 (4%)
8 (1%)
158 (12%)

235 (72%)
9 (3%)
22 (7%)
15 (4%)
5 (1%)
41 (13%)

0.2487
0.7506
0.0007
0.3282
< 0.0001
0.0996
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Table 2  Baseline characteristics
after propensity matching

Characteristic

CCTA (n = 327)

Stress Echo (n = 324)

p-value

Male Sex, no. (%)
Age (years)
Mean ± SD
Range
Hypertension, no. (%)
Hyperlipidemia, no. (%)
Diabetes Mellitus, no. (%)
Active Smoker, no. (%)
CAD Consortium Score (%)
Indication, no. (%)
ATCP
Angina
Dyspnea
Palpitations
Syncope
Other

197 (60%)

177 (55%)

0.147

51 ± 8.6
35–70
160 (49%)
153 (47%)
41 (13%)
31 (9%)
10.9 ± 7.7

51 ± 8.7
35–70
177 (55%)
148 (46%)
61 (19%)
31 (10%)
10.1 ± 7.2

0.659

245 (75%)
9 (3%)
18 (5.5%)
18 (5.5%)
1 (0%)
36 (11%)

233 (72%)
8 (2%)
22 (7%)
15 (5%)
5 (1%)
41 (13%)

matching using the CAD Consortium score was used to
compare CCTA with ESE.

Results
In the specified six-and-a-half-year time interval, a total of
11,636 patients undergoing any form of noninvasive cardiac
testing were screened. Of those screened, 2,864 patients underwent CCTA and 1,285 of those were included after excluding
patients who did not meet study parameters described above.
A total of 985 patients who underwent ESE were screened.
Of these, 327 were eligible for inclusion. The initial patient
demographics are displayed in Table 1. There were statistically
significant baseline differences in the populations of patients
undergoing CCTA versus ESE. Notably, patients undergoing
ESE were more likely to be female and have diabetes mellitus. After propensity matching, there remained 327 and 324
patients in the CCTA and ESE cohorts, respectively. The
patients had similar average CAD consortium scores around
10%. The demographics of the patients included in each propensity-matched cohort are displayed in Table 2.
According to the 2018 Final Medicare Physician Fee
Schedule, the price of ESE was 239 United States Dollars
(USD) whereas the cost of CCTA was 432 USD [9]. A total
Table 3  Differences in number
and cost of downstream
testing for propensity matched
cohort of patients initially
evaluated with CCTA and stress
echocardiography

Total cost of initial test (USD)
Number of downstream tests, no
Percentage undergoing additional
testing
Overall testing cost (USD)

0.146
0.776
0.0269
0.970
0.1544
0.4916

of 18.5 percent of patients with a normal ESE result underwent some additional form of cardiac testing in the next five
years compared to 12.8 percent of patients with a normal
CCTA. The absolute difference in total number of downstream tests between both study groups was 5.7 percent, correlating to an additional downstream test for every 17 ESE
performed. When factoring the costs of the initial test as well
as the downstream tests, the ESE group was associated with
overall lower costs, 351 USD compared to the CCTA group
which averaged 496 USD, p < 0.0001 (see Table 3).

Discussion
This study set out to examine the downstream effects of negative ESE or CCTA when chosen as the initial noninvasive
test for suspected CAD. As described in detail above, the
choice of ESE was found to have a greater number of downstream tests, which is in line with the “warranty period” of
CCTA. However, when accounting for the cost of the initial
negative test, ESE was associated with a lower total cost. We
originally hypothesized that CCTA would be associated with
both total lower number of downstream tests and total cost
due to the previously published negative predictive value of
CCTA in RCTs.
CCTA (n = 327)

Stress Echo (n = 324)

p-value

432.36
42
12.8%

239.04
60
18.5%

n/a
0.0296
0.0296

496.35 ± 185.35

351.48 ± 270.64

< 0.0001
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In the past few years, two large RCTs, PROMISE and
SCOT-HEART, have compared clinical outcomes between
groups randomized to functional or anatomic testing with
CCTA. As a result of these two and other studies, the European Society of Cardiology (ESC) guidelines for chronic
coronary endorsed CCTA as a Class I recommendation for
initial test to diagnose CAD [10]. As found in the PROMISE
trial, there was no major difference between the CCTA and
functional testing arms when comparing the primary composite outcome of death from any cause, nonfatal myocardial infarction (MI), hospitalization for unstable angina, or
procedural complication. However, the CCTA arm showed
statistically significant increases in total radiation, a 4.1%
absolute increase in diagnostic cardiac catheterizations,
and a 3.0% absolute increase in revascularization [6]. The
SCOT-HEART trial remarkably showed that patients undergoing an anatomic evaluation with CCTA had a lower primary endpoint of death from CAD or nonfatal MI than the
standard care group, predominately driven by nonfatal MI
[11]. The authors hypothesized that this was due to increased
preventive therapy for primary prevention of MI including
statins, aspirin, lifestyle interventions, and revascularization
when appropriate. They also hypothesized this may be due
to increased patient motivation given objective measure of
disease.
Notably, ESE was underrepresented in the functional
imaging control group in both landmark studies. Specifically, only 22% of patients underwent ESE compared to 67%
undergoing nuclear testing in the PROMISE trial [6]. Less
than one percent of patients underwent ESE in the SCOTHEART trial [5]. Furthermore, while the authors are aware
of at least one prospective RCT comparing clinical outcomes
between myocardial perfusion imaging (MPI) and CCTA,
we are unaware of any studies directly comparing ESE to
CCTA in the outpatient setting [12]. Upon our review of the
literature, there has only been one RCT comparing ESE vs
CCTA. Levsky et al. enrolled 400 patients without known
CAD presenting with chest pain to the emergency department and showed that ESE and CCTA led to similar results
in major adverse cardiac events (MACE), invasive angiography, and revascularization by one year. Patients in the CCTA
arm were admitted more often and spent more days in the
hospital than the patients in the ESE group [13].
Moreover, ESE possesses a few clear advantages when
compared to CCTA. Despite the growing use of CCTA,
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ESE remains widely available in the clinic and emergency
department settings with minimal equipment requirements.
In addition to wall motion analysis, additional prognostic data can be derived, such as metabolic equivalents,
heart rate response, and exercise induced hypertension.
For patients being referred for cardiac testing with chief
complaint of dyspnea, ESE can provide diagnostic information in nonischemic etiologies, including exerciseinduced diastolic dysfunction, pulmonary hypertension,
and severity of mitral valve disease. Importantly, ESE does
not expose the patient to ionizing radiation. These advantages are in addition to the post cost savings discussed
above.
Our study has several strengths. First, as fewer downstream tests were performed in the CCTA arm, it shows
that providers likely act in light of the perceived “warranty
period” of a normal CCTA. Additionally, our study benefits
from the comprehensive electronic medical record available through the Department of Defense health system. As a
result, over 11,000 patients were screened. Lastly, propensity
matching was completed as outlined above, further strengthening the comparison between the two arms [4].
Our trial has some limitations. Most importantly, it
should be noted that the cost-analysis cannot be used to
compare CCTA and ESE as a whole because our analysis
does not include patients with positive results. Further, while
the studied populations underwent propensity matching,
this cannot eliminate all potential cofounders present in this
retrospective analysis. Second, the results may lack generalizability given the population studied was Tricare beneficiaries. This is exemplified by the notable low pre-test probability noted in our study even after excluding very-low risk
patients with a CAD consortium pretest probability of less
than five percent. Last, it is retrospective and thus it should
principally be viewed as hypothesis-generating (Fig. 1).
This study demonstrates an association between ESE
with higher total number of downstream tests as well as
lower costs when compared to CCTA. These findings are
unexpected and potentially worthwhile as the cardiology
community moves towards CCTA as a first line test for
suspected CAD. As these findings are retrospective, future
RCTs specifically examining the financial and clinical outcomes of CCTA compared with ESE would bring further
clarity to these questions.
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Fig. 1  Screening, inclusion,
and propensity matching. CCTA
coronary computed tomography angiography. ESE exercise
stress echocardiogram. Figure
created in Microsoft Publisher
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